Director, HEOR Strategy - Oncology

Director, HEOR Strategy, CLL & Heme-Oncology (HEOR-S)

Responsibilities:
- Direct, develop, organize, and implement Value & Evidence (V&E) strategy for Chronic Lymphocytic Leukemia (CLL) and disease adjacencies to support expeditious asset development toward registration, PR&A, and market launch in compliance with national and international regulations.
- Co-create holistic oncology value evidence strategy with V&E pillars and cross-functional partners; co-create PCM deliverables, MHI Worldwide Scientific Plan, and Value & Evidence Plans (VEP).
- Direct the design, conduct, and analysis of projects across multiple programs with V&E Centers of Excellence (PCOR, VAC, RWE, EPE, MPS), ensuring ethical, scientific, regulatory, commercial, and quality requirements are met or exceeded; accountable for project execution and budget.
- Engage cross-functionally for CLL; communicate findings to internal leadership and external stakeholders (HTAs/payers, patient advocacy groups, KOLs).
- Develop and execute V&E product life-cycle and labeling strategies in the post-marketing setting, integrating customer value-demonstration needs, commercial direction, and science realities.
- Provide strategic V&E support of commercialization, including facilitating market access, and growing/defending market.
- Ensure end-to-end delivery of the V&E book of work under remit (strategy development through content pull-through).
- Partner with MHI, IMAP, and relevant V&E pillars to accelerate global patient access.
- Partner to shape the CLL oncology patient access policy environment with HTA/payers, clinical practice guideline organizations, and US oncology pathway stakeholders; establish external alliances to drive fit-for-purpose evidence generation.
- Develop and maintain CLL oncology research partnerships with academic and community oncology centers to demonstrate clinical, economic, humanistic, and societal value.

Qualifications (Required/Preferred):
- Advanced degree: MSc, MPH, or MBA with 10+ years relevant experience; or PharmD/PhD with 7+ years in HEOR, market access, or related research field.
- Deep expertise in HEOR methods: health economic modeling, PROs, statistics, real-world evidence; strong experience with registry/observational study design, execution, analysis, and interpretation.
- Proven oncology HEOR and market access experience across pipeline, launch, in-line, and lifecycle management.
- Strong understanding of oncology health technology development and commercialization (drugs and diagnostic devices).
- Proven ability as an influencer in matrixed environments; align partners across medical, clinical, access, affiliates, and commercial without direct authority.
- Track record in HTA/value assessment and engagement with NCCN, ESMO-MCBS, NICE, IQWiG, CADTH, MSAC, ICER, and similar organizations.
- Experience partnering with IDNs, GPOs, and collaborative groups for external research.
- Ability to independently lead complex HEOR initiatives (e.g., SLRs, ITCs, NMAs, PRO/PED studies, RWE, DCEs, economic models, non-interventional studies).
- Strong strategic judgment; excellent English communication (oral and written); strong project management (contracting, budgeting, vendor management).
- Highly organized, proactive, adaptable; people leadership experience preferred.

Benefits:
- Paid time off (vacation, holidays, sick), medical/dental/vision insurance, and 401(k) for eligible employees.
- Eligible for long-term incentive programs.